Vaccines work by teaching your immune system to recognize and fight a specific germ before you ever encounter it naturally. They introduce a harmless piece or version of a pathogen, your body mounts a defense against it, and your immune system stores a memory of that encounter so it can respond faster and harder if the real infection shows up later. The entire process relies on the same biological machinery your body uses to fight off any illness, just without the risks of the actual disease.
What Happens Inside Your Body After a Vaccine
Within minutes of a vaccination, your innate immune system kicks in. Immune cells near the injection site detect the foreign material and begin engulfing it. The most important of these early responders are dendritic cells, which are uniquely powerful at breaking down vaccine material into small protein fragments and displaying those fragments on their surface like flags.
These dendritic cells then migrate from the injection site to your nearest lymph node, where the adaptive immune system takes over. Inside the lymph node, two critical things happen simultaneously. First, specialized white blood cells called helper T cells recognize the protein fragments being displayed and activate. Second, B cells whose surface receptors happen to match the vaccine’s target protein also activate and begin migrating toward the T cells.
What follows is a partnership. Helper T cells stimulate B cells through direct contact and chemical signals, pushing B cells to multiply rapidly. During this expansion, B cells undergo a refinement process: they shuffle and fine-tune their antibody genes, producing increasingly precise antibodies that bind more tightly to the target. The highest-performing B cells survive this selection process and become antibody factories, pumping out proteins that can neutralize the real pathogen on contact. Some of these B cells migrate to your bone marrow and become long-lived plasma cells that continue producing antibodies for months or years. Others become memory B cells that lie dormant until they’re needed again.
How Immune Memory Protects You Long-Term
The real value of a vaccine isn’t the antibodies circulating right after your shot. It’s the memory cells your body creates. Memory B cells and memory T cells can persist for years, and when they encounter the same pathogen again, they activate far faster than your immune system could respond from scratch. Instead of taking a week or more to mount a defense (during which you’d get sick), memory cells can ramp up within hours.
This is also why booster doses matter. Research on children who received a live influenza vaccine found that memory B cells increased after a single dose, but rose significantly more after a second dose. The same pattern held for T cells: the proportion of immune cells capable of mounting a multi-pronged attack increased after dose one and jumped again after dose two. Each exposure refines and strengthens the immune memory, which is why some vaccines require multiple doses spaced over weeks or months.
Types of Vaccines and How They Differ
Live-Attenuated Vaccines
These contain a weakened version of the actual virus or bacterium, created by repeatedly growing it in lab cultures until it can barely cause illness. Because the weakened germ can still replicate a little inside your body, your immune system responds almost identically to how it would during a real infection. That’s why live vaccines like the measles, mumps, and rubella (MMR) shot typically produce strong, long-lasting immunity with just one or two doses.
Inactivated and Subunit Vaccines
Inactivated vaccines use germs that have been killed entirely, while subunit vaccines use only a specific piece of the germ, like a surface protein or a deactivated toxin. Since nothing in these vaccines can replicate, the immune response they generate is weaker and primarily based on antibody production, with less of the cellular immunity that live vaccines trigger. This is why inactivated vaccines generally require multiple doses. The first dose primes the immune system, and a protective response typically doesn’t develop until the second or third dose.
mRNA Vaccines
Rather than introducing any part of the actual virus, mRNA vaccines deliver a small strip of genetic instructions that tells your cells how to build one specific viral protein, usually a protein found on the virus’s outer surface. Your cells read those instructions, manufacture the protein, and display it on their surface, where the immune system detects it as foreign and responds. The mRNA never enters the cell’s nucleus and doesn’t interact with your DNA. Once the protein is made, cells break down the mRNA quickly.
Viral Vector Vaccines
These use a harmless virus (often an adenovirus, a common type that causes colds) that has been modified so it can’t replicate. Scientists insert genetic instructions for a target protein into this carrier virus. When the vector infects your cells, it delivers those instructions, your cells produce the foreign protein, and the immune system responds. Because the vector actually enters cells the way a real virus would, these vaccines tend to trigger both antibody production and strong cellular immunity.
What Adjuvants Do
Many inactivated and subunit vaccines include ingredients called adjuvants, which amplify the immune response. The most common is aluminum salts, used in vaccines against hepatitis A, hepatitis B, diphtheria, tetanus, and others. Aluminum salts work by creating a mild inflammatory reaction at the injection site, which recruits a wave of immune cells including dendritic cells, monocytes, and natural killer cells to the area. The aluminum also interacts directly with dendritic cell membranes, triggering a chain of signals that helps these cells absorb the vaccine’s antigens and present them more effectively. This is why the injection site can feel sore or slightly swollen: that local inflammation is the adjuvant doing its job.
How Vaccines Are Tested Before Approval
Before any vaccine reaches the public, it passes through three phases of clinical trials. Phase 1 involves 20 to 100 healthy volunteers and focuses primarily on safety: identifying adverse reactions at different doses and getting early signals about whether the vaccine triggers an immune response. Phase 2 expands to hundreds of participants across varying health statuses and demographic groups, providing more safety data and initial evidence of effectiveness. Phase 3 involves thousands of people and is where researchers determine whether the vaccine actually prevents disease. Participants are split into vaccinated and control groups, and the number of infections in each group is compared to measure real-world efficacy. This phase also captures rarer side effects that wouldn’t appear in smaller studies.
After approval, monitoring continues. The CDC and FDA jointly run multiple surveillance systems to catch safety signals that emerge once millions of people receive the vaccine. VAERS collects reports of any health problems that occur after vaccination, even if the connection isn’t yet confirmed. The Vaccine Safety Datalink conducts active studies using health records from large medical systems. And the Clinical Immunization Safety Assessment project brings together vaccine safety experts to evaluate complex cases.
How Vaccines Protect Communities
When enough people in a population are immune to a disease, the pathogen can’t find enough susceptible hosts to spread, which indirectly protects people who can’t be vaccinated, like newborns or those with compromised immune systems. The threshold for this community protection varies by disease. Measles, one of the most contagious viruses known, requires vaccination coverage above 90% to 95% to prevent transmission. Even a 5% exemption rate can undermine that protection and allow outbreaks. Less contagious diseases have lower thresholds, but the principle is the same: individual vaccination is also a collective act.